scholarly journals Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma

2010 ◽  
Vol 21 (10) ◽  
pp. 2069-2074 ◽  
Author(s):  
N. Niitsu ◽  
M. Okamoto ◽  
J.-i. Tamaru ◽  
T. Yoshino ◽  
N. Nakamura ◽  
...  
2016 ◽  
Vol 58 (5) ◽  
pp. 1178-1183
Author(s):  
Robert Carr ◽  
Hilal Ozdag ◽  
Nilgun Tekin ◽  
Timothy Morris ◽  
Paulette Conget ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17025-e17025
Author(s):  
Xiaojian LIU

e17025 Background: Cervical lymphoma is a rare condition and may be difficult to diagnose and treatment. Large B-cell lymphoma is among the most common sub-type of Cervical Lymphoma.No standard treatments for patients with primary cervix large B-cell lymphoma have been introduced currently. Only case reports published in the literature and indicated the R-CHOP regimens in combination with involved field radiation therapy (RT) are effective. Shanghai Cancer Center is one of the top pathological consultant center in China. We retrospectively analyse the 37 patients with primary cervix large B-cell lymphoma and outcome after R-CHOP in combination with RT. Methods: Thirty-seven untreated primary cervix large B-cell lymphoma patients received R-CHOP like regimens. Fourteen of them underwent subsequent RT. Thirteen of them received subsequent salvage chemotherapy. Results: Of 37 patients underwent R-CHOP chemotherapy, only 3 patients received the radical surgery. An overall response rate (ORR) was 78.3% after completion of chemotherapy.The PFS and OS rate at 5 years were 58% and 69%, respectively. For 14 patients who received RT after R-CHOP, an estimated ORR were 89.2%. For all patients, The PFS reached the platform after 2 years follow up and the OS after 3 years according to the survival curve analysis. The international prognostic index (IPI) score were the only predictor of worse outcome. Conclusions: R-CHOP regimens plus involved field radiation therapy led high response rate in primary cervix large B-cell lymphoma. Patients with high IPI had a trend of less satisfied with R-CHOP regimens plus IFRT. Future prospective and multicenter studies are needed. By the way, we are conducting a gene expression profile between DLBCL-unspecified and primary cervix large B-cell lymphoma by NGS in order to get the valuable information to improve the treatment outcome even by using some targeted drugs. The data will be show in the next few months.


2020 ◽  
Vol 9 (10) ◽  
pp. 6116-6127
Author(s):  
Yu-Ying Wu ◽  
Jie-Yu You ◽  
Cih-En Huang ◽  
Chia-Chen Hsu ◽  
Yi-Yang Chen ◽  
...  

2008 ◽  
Vol 32 (12) ◽  
pp. 1837-1841 ◽  
Author(s):  
Nozomi Niitsu ◽  
Masataka Okamoto ◽  
Hirokazu Nakamine ◽  
Masami Hirano

2011 ◽  
Vol 52 (10) ◽  
pp. 1867-1872 ◽  
Author(s):  
Luigi Marcheselli ◽  
Raffaella Marcheselli ◽  
Alessia Bari ◽  
ElianaValentina Liardo ◽  
Fortunato Morabito ◽  
...  

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4568-4568
Author(s):  
Wei Sang ◽  
Yuhan Ma ◽  
Xiangmin Wang ◽  
Ziyuan Shen ◽  
Linyan Xu ◽  
...  

Abstract De novo CD5 positive diffuse large B cell lymphoma (CD5+ DLBCL) has poor survival in the era of immunochemotherapy. We conducted a multi-center retrospective study to explore the clinicopathologic characteristics, genomic profiling and prognostic elements of 61 CD5+ DLBCL and 60 CD5- DLBCL patients in China. In contrast with CD5- DLBCL, elderly onset, advanced stage, central nervous system (CNS) involvement, as well as MYC/BCL-2 and P53 overexpression were more prevalent in CD5+ DLBCL. In addition, most of CD5+ DLBCL patients were of non-germinal center B-cell-like (non-GCB) and activated B-cell-like (ABC) subtype according to immunohistochemistry and Lymph2Cx assay. Genetic analysis by next generation sequencing (NGS) showed the proportion of MCD subtype in CD5+ DLBCL was higher than that of CD5- DLBCL (50% vs 5%, p = 0.0007). Compared with CD5- cohort, CD5+ DLBCL patients showed poorer 5-year overall survival (OS) (70.9% vs 39.0%, p<0.001), independent of cell-of-origin and MYC/BCL-2, P53 and BCL-6 status. Multivariate analysis showed that age >76 years, advanced stage, CNS involvement and hypoalbuminemia were independent factors associated with poor prognosis in CD5+ DLBCL. In conclusion, CD5+ DLBCL conveyed poor prognosis and showed distinctive clinicopathologic characteristics and predominant genetic features of ABC and MCD subtypes. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document